{"schema_version":"secwatch.filing_event.v1","accession":"0001773751-24-000337","form_type":"8-K","ticker":"HIMS","cik":"0001773751","company_name":"Hims & Hers Health, Inc.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.562061+00:00","generated_at":"2026-05-30T06:13:12.717474+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Hims & Hers Q3 rev $401.6M (+77% YoY), net income $75.6M, raises FY guidance","bullets":["Q3 2024: Revenue $401.6M (+77% YoY), net income $75.6M (vs -$7.6M), Adj EBITDA $51.1M.","Subscribers 2.0M (+44% YoY); over 1M using personalized solutions; ex-GLP-1 sub growth 40% YoY.","FY 2024 guidance raised: Revenue $1.460-1.465B, Adj EBITDA $173-178M.","Weight loss offering: oral GLP-1 $100M annual run rate; 80K reports of supply shortage; planning liraglutide in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001773751-24-000337","json":"https://secwatch.observer/filing/0001773751-24-000337.json","markdown":"https://secwatch.observer/filing/0001773751-24-000337.md","text":"https://secwatch.observer/filing/0001773751-24-000337.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1773751/000177375124000337/0001773751-24-000337-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1773751/000177375124000337/hims-20241104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:13:12.717474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}